MannKind (MNKD) to Release Earnings on Wednesday

Key Points

• MannKind (MNKD) is set to release its Q2 2025 earnings on August 6th, with analysts forecasting earnings of $0.04 per share and revenue of $77.82 million.
• The company's stock opened at $3.82 and has experienced a 3.5% decline, with a market capitalization of $1.16 billion.
• Recent analyst ratings have been positive, with seven analysts rating the stock as a buy and a target price consensus of $9.86.

MannKind (NASDAQ:MNKD - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $77.82 million for the quarter.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. MannKind had a net margin of 10.12% and a negative return on equity of 32.41%. The firm had revenue of $78.35 million during the quarter, compared to the consensus estimate of $75.86 million. During the same quarter in the previous year, the firm posted $0.05 EPS. The business's revenue for the quarter was up 18.1% compared to the same quarter last year. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Performance

Shares of MannKind stock traded down $0.03 on Friday, reaching $3.75. 2,543,159 shares of the stock were exchanged, compared to its average volume of 2,550,986. The firm's 50 day moving average is $3.91 and its 200-day moving average is $4.70. MannKind has a one year low of $3.51 and a one year high of $7.63. The firm has a market cap of $1.14 billion, a PE ratio of 37.50 and a beta of 1.02.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on MNKD shares. Wall Street Zen cut shares of MannKind from a "buy" rating to a "hold" rating in a research report on Saturday. Royal Bank Of Canada decreased their price target on shares of MannKind from $10.00 to $8.00 and set an "outperform" rating for the company in a research report on Wednesday, July 23rd. HC Wainwright upgraded shares of MannKind to a "buy" rating and set a $9.00 price target for the company in a research report on Wednesday, July 16th. Finally, Mizuho assumed coverage on shares of MannKind in a research report on Thursday, April 10th. They issued an "outperform" rating and a $12.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, MannKind currently has an average rating of "Buy" and an average price target of $9.86.

Insider Buying and Selling at MannKind

In other MannKind news, EVP David Thomson sold 32,179 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total value of $150,597.72. Following the transaction, the executive vice president directly owned 772,427 shares of the company's stock, valued at approximately $3,614,958.36. This trade represents a 4.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven B. Binder sold 80,144 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total transaction of $375,875.36. Following the completion of the transaction, the director directly owned 1,006,611 shares in the company, valued at $4,721,005.59. This trade represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 266,198 shares of company stock worth $1,143,244. 3.00% of the stock is owned by insiders.

Institutional Trading of MannKind

Several institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC increased its stake in shares of MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company's stock worth $278,000 after purchasing an additional 9,160 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of MannKind by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company's stock worth $1,059,000 after purchasing an additional 6,079 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of MannKind by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company's stock worth $3,374,000 after purchasing an additional 53,202 shares in the last quarter. Hedge funds and other institutional investors own 49.55% of the company's stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.